Dawei Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dawei Huang has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Yuling Shi
Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China
12 shared publications - Adrian Wiestner
Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
7 shared publications - Arthur L. Shaffer
Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
7 shared publications - Björn Häupl
University Hospital Frankfurt 3 Department of Medicine, Hematology and Oncology Goethe University Frankfurt, Frankfurt am Main, Germany
7 shared publications - Carleen Klumpp-Thomas
National Center for Advancing Translational Sciences
7 shared publications - Clare Sun
Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
7 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9453
Author Correction: Double-stranded RNA and ROS scavenging nanoplatform for modulating skin inflammation
- 3 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9453
Open AccessAuthor Correction: Double-stranded RNA and ROS scavenging nanoplatform for modulating skin inflammation
- Open Access
- 1 September 2026
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 19, 1-10
Complete Skin Clearance is Associated with HADS-Defined Absence of Anxiety and Depressive Symptoms After IL-17A Inhibitor Treatment in Moderate-to-Severe Psoriasis: Evidence from the SPEECH Cohort
Background: Psoriasis is a chronic immune-mediated disease associated with anxiety, depressive symptoms, and impaired quality of life, potentially involving interacting psychosocial and inflammatory pathways. During biologic treatment, psychological symptoms may improve alongside skin disease, but whether complete skin clearance (CSC) is associated with Hospital Anxiety and Depression Scale (HADS)-defined absence of anxiety and depressive symptoms remains unclear. Objective: To examine whether CSC, defined as PASI100, was associated with HADS-defined absence of anxiety and depressive symptoms after 12-week IL-17A inhibitor treatment in moderate-to-severe psoriasis. Methods: Patients receiving IL-17A inhibitors were identified from the Shanghai Psoriasis Effectiveness Evaluation CoHort (SPEECH). Eligible patients had complete baseline data, week-12 Psoriasis area and severity index (PASI) and HADS assessments. PASI responses represented percentage improvement from baseline and were categorized as PASI< 75, PASI75–< 100, or PASI100. The primary outcomes were week-12 HADS-A = 0 and HADS-D = 0, and the secondary outcomes were week-12 HADS-A and HADS-D as continuous outcomes. Logistic and linear regression, subgroup, and sensitivity analyses were performed. Results: Among 233 patients, 32 (13.7%) achieved PASI< 75, 99 (42.5%) PASI75–< 100, and 102 (43.8%) PASI100. Baseline HADS-A and HADS-D were comparable across groups. Compared with PASI100, PASI75–< 100 was associated with lower odds of HADS-A = 0 (adjusted OR [aOR], 0.40; 95% confidence interval [CI], 0.20– 0.78) and HADS-D = 0 (aOR, 0.48; 95% CI, 0.25– 0.95), and higher week-12 HADS-A (adjusted β, 1.10; 95% CI, 0.34– 1.86) and HADS-D (adjusted β, 0.95; 95% CI, 0.18– 1.72). For PASI< 75 versus PASI100, the corresponding aORs for HADS-A = 0 and HADS-D = 0 were 0.22 (95% CI, 0.08– 0.62) and 0.27 (95% CI, 0.09– 0.81), respectively. Subgroup and sensitivity analyses yielded consistent findings. Conclusion: CSC was associated with a higher likelihood of HADS-defined absence of anxiety and depressive symptoms in the treatment of moderate-to-severe psoriasis.
- 1 September 2026
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 19, 1-10
Open AccessComplete Skin Clearance is Associated with HADS-Defined Absence of Anxiety and Depressive Symptoms After IL-17A Inhibitor Treatment in Moderate-to-Severe Psoriasis: Evidence from the SPEECH Cohort
Background: Psoriasis is a chronic immune-mediated disease associated with anxiety, depressive symptoms, and impaired quality of life, potentially involving interacting psychosocial and inflammatory pathways. During biologic treatment, psychological symptoms may improve alongside skin disease, but whether complete skin clearance (CSC) is associated with Hospital Anxiety and Depression Scale (HADS)-defined absence of anxiety and depressive symptoms remains unclear. Objective: To examine whether CSC, defined as PASI100, was associated with HADS-defined absence of anxiety and depressive symptoms after 12-week IL-17A inhibitor treatment in moderate-to-severe psoriasis. Methods: Patients receiving IL-17A inhibitors were identified from the Shanghai Psoriasis Effectiveness Evaluation CoHort (SPEECH). Eligible patients had complete baseline data, week-12 Psoriasis area and severity index (PASI) and HADS assessments. PASI responses represented percentage improvement from baseline and were categorized as PASI< 75, PASI75–< 100, or PASI100. The primary outcomes were week-12 HADS-A = 0 and HADS-D = 0, and the secondary outcomes were week-12 HADS-A and HADS-D as continuous outcomes. Logistic and linear regression, subgroup, and sensitivity analyses were performed. Results: Among 233 patients, 32 (13.7%) achieved PASI< 75, 99 (42.5%) PASI75–< 100, and 102 (43.8%) PASI100. Baseline HADS-A and HADS-D were comparable across groups. Compared with PASI100, PASI75–< 100 was associated with lower odds of HADS-A = 0 (adjusted OR [aOR], 0.40; 95% confidence interval [CI], 0.20– 0.78) and HADS-D = 0 (aOR, 0.48; 95% CI, 0.25– 0.95), and higher week-12 HADS-A (adjusted β, 1.10; 95% CI, 0.34– 1.86) and HADS-D (adjusted β, 0.95; 95% CI, 0.18– 1.72). For PASI< 75 versus PASI100, the corresponding aORs for HADS-A = 0 and HADS-D = 0 were 0.22 (95% CI, 0.08– 0.62) and 0.27 (95% CI, 0.09– 0.81), respectively. Subgroup and sensitivity analyses yielded consistent findings. Conclusion: CSC was associated with a higher likelihood of HADS-defined absence of anxiety and depressive symptoms in the treatment of moderate-to-severe psoriasis.
- Open Access
- 13 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Double-stranded RNA and ROS scavenging nanoplatform for modulating skin inflammation
Double-stranded RNA (dsRNA) and reactive oxygen species (ROS) contribute to the exacerbation of skin inflammatory diseases such as psoriasis and atopic dermatitis. While antioxidant strategies have been extensively explored, approaches to neutralize pathogenic dsRNA remain limited. Here, we show that Mo90Ce10, a cerium-doped polyoxometalate, concurrently targets dsRNA and ROS to mitigate cutaneous inflammation. In vitro, Mo90Ce10 scavenges ROS and suppresses type I interferon responses by directly binding dsRNA through its oxygen-rich, hydrogen bond-forming surface. Its structural template, {Mo154}, exhibits weaker activity. In vivo, Mo90Ce10 reduces disease severity, dsRNA-induced inflammation, ROS burden, and neutrophil infiltration. Leveraging its negative charge and self-assembly properties, we further develop a transdermal platform by complexing Mo90Ce10 with the cationic peptide TD-1 and co-loading methotrexate, thereby enhancing drug penetration andtherapeutic efficacy while reducing recurrence. Together, these findings establish Mo90Ce10 as a multifunctional modulator of dsRNA- and ROS-driven inflammation and a promising transdermal delivery platform for inflammatory diseases.
- 13 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessDouble-stranded RNA and ROS scavenging nanoplatform for modulating skin inflammation
Double-stranded RNA (dsRNA) and reactive oxygen species (ROS) contribute to the exacerbation of skin inflammatory diseases such as psoriasis and atopic dermatitis. While antioxidant strategies have been extensively explored, approaches to neutralize pathogenic dsRNA remain limited. Here, we show that Mo90Ce10, a cerium-doped polyoxometalate, concurrently targets dsRNA and ROS to mitigate cutaneous inflammation. In vitro, Mo90Ce10 scavenges ROS and suppresses type I interferon responses by directly binding dsRNA through its oxygen-rich, hydrogen bond-forming surface. Its structural template, {Mo154}, exhibits weaker activity. In vivo, Mo90Ce10 reduces disease severity, dsRNA-induced inflammation, ROS burden, and neutrophil infiltration. Leveraging its negative charge and self-assembly properties, we further develop a transdermal platform by complexing Mo90Ce10 with the cationic peptide TD-1 and co-loading methotrexate, thereby enhancing drug penetration andtherapeutic efficacy while reducing recurrence. Together, these findings establish Mo90Ce10 as a multifunctional modulator of dsRNA- and ROS-driven inflammation and a promising transdermal delivery platform for inflammatory diseases.
- Open Access
- 1 May 2026
- Published by Taylor & Francis in Psoriasis: Targets and Therapy
- Vol. ume 16, 1-10
Development of Predictive Models for NB-UVB Treatment Efficacy and Safety in Psoriasis
Background: Psoriasis is a chronic inflammatory skin disease. Narrow-band ultraviolet B (NB-UVB) phototherapy is an effective, cost-efficient, and safe treatment for plaque psoriasis; however, predictors of treatment response remain limited. Objective: To develop predictive models for the efficacy and safety of NB-UVB phototherapy in patients with plaque psoriasis. Methods: A total of 252 patients with plaque psoriasis were enrolled and received 12 weeks of NB-UVB phototherapy. Baseline clinical data and blood samples for genetic analysis were collected. A genome-wide association study (GWAS) was performed to identify single-nucleotide polymorphisms (SNPs) associated with treatment response and adverse events (AEs). Results: Using a suggestive genome-wide significance threshold (P < 1× 10− 5), the SLC7A13 rs35314286 TA allele and DYNC1H1 rs941636 A allele showed suggestive associations with better efficacy after 4 weeks of NB-UVB treatment. Seven ATP2B2 SNPs and ten PSMB7 SNPs showed suggestive associations with achievement of Psoriasis area and severity index (PASI) 75 at week 12. Two KCNA2 SNPs, seven THSD7B SNPs, and one TENM4 SNP were identified as candidate markers for the occurrence of AEs. Conclusion: Predictive models of NB-UVB treatment response in psoriasis were subsequently established and achieved area under the curve (AUC) values ranging from 0.80 to 0.85. Further validation in independent external cohorts is needed before clinical application.
- 1 May 2026
- Published by Taylor & Francis in Psoriasis: Targets and Therapy
- Vol. ume 16, 1-10
Open AccessDevelopment of Predictive Models for NB-UVB Treatment Efficacy and Safety in Psoriasis
Background: Psoriasis is a chronic inflammatory skin disease. Narrow-band ultraviolet B (NB-UVB) phototherapy is an effective, cost-efficient, and safe treatment for plaque psoriasis; however, predictors of treatment response remain limited. Objective: To develop predictive models for the efficacy and safety of NB-UVB phototherapy in patients with plaque psoriasis. Methods: A total of 252 patients with plaque psoriasis were enrolled and received 12 weeks of NB-UVB phototherapy. Baseline clinical data and blood samples for genetic analysis were collected. A genome-wide association study (GWAS) was performed to identify single-nucleotide polymorphisms (SNPs) associated with treatment response and adverse events (AEs). Results: Using a suggestive genome-wide significance threshold (P < 1× 10− 5), the SLC7A13 rs35314286 TA allele and DYNC1H1 rs941636 A allele showed suggestive associations with better efficacy after 4 weeks of NB-UVB treatment. Seven ATP2B2 SNPs and ten PSMB7 SNPs showed suggestive associations with achievement of Psoriasis area and severity index (PASI) 75 at week 12. Two KCNA2 SNPs, seven THSD7B SNPs, and one TENM4 SNP were identified as candidate markers for the occurrence of AEs. Conclusion: Predictive models of NB-UVB treatment response in psoriasis were subsequently established and achieved area under the curve (AUC) values ranging from 0.80 to 0.85. Further validation in independent external cohorts is needed before clinical application.
- Open Access
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Identifying an Early Improvement Cutoff in Psoriasis Area and Severity Index for Outcome Prediction Across Systemic Treatments
Background: Early identification of treatment response is clinically important in psoriasis management, as it may facilitate timely treatment modification and reduce exposure to ineffective therapies. Although early improvement in the Psoriasis Area and Severity Index (PASI) has been associated with long‐term outcomes for individual therapies, a broadly applicable early PASI threshold across different treatment modalities in real‐world practice remains unclear. Objectives: To evaluate the predictive value of early PASI improvement for subsequent PASI90 achievement across multiple psoriasis treatment modalities and to identify a clinically meaningful early PASI response threshold. Methods: This prospective, multicenter real‐world cohort study (approval no. 2020‐36) included adult patients with moderate‐to‐severe plaque psoriasis receiving methotrexate, phototherapy, interleukin (IL)‐17 inhibitors, or IL‐23 inhibitors. Receiver operating characteristic (ROC) curve analyses were used to evaluate the predictive performance of week‐4 PASI improvement for achieving PASI90 at 3 and 6 months. The optimal early response threshold was identified using the Youden Index. Multivariable logistic regression analyses were conducted to assess the independent association between early PASI response and subsequent PASI90 achievement. Results: A total of 2023 patients were included in the analysis. The optimal week‐4 PASI improvement threshold for predicting PASI90 at 3 months was 62% for IL‐17 inhibitors, 62% for IL‐23 inhibitors, 59% for methotrexate, and 61% for phototherapy. Multivariable logistic regression analyses further demonstrated that a PASI improvement of approximately 60% at Week 4 was independently associated with a higher likelihood of achieving PASI90 at 3 months. Conclusions: Achieving PASI60 at Week 4 serves as a consistent early indicator of subsequent PASI90 response across multiple psoriasis treatment modalities. These findings suggest that PASI60 may represent a potentially generalizable early‐response threshold; however, external validation in independent populations is required before its incorporation into routine clinical decision‐making. Trial Registration: Chinese Clinical Trial Registry: ChiCTR2000036186
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Open AccessIdentifying an Early Improvement Cutoff in Psoriasis Area and Severity Index for Outcome Prediction Across Systemic Treatments
Background: Early identification of treatment response is clinically important in psoriasis management, as it may facilitate timely treatment modification and reduce exposure to ineffective therapies. Although early improvement in the Psoriasis Area and Severity Index (PASI) has been associated with long‐term outcomes for individual therapies, a broadly applicable early PASI threshold across different treatment modalities in real‐world practice remains unclear. Objectives: To evaluate the predictive value of early PASI improvement for subsequent PASI90 achievement across multiple psoriasis treatment modalities and to identify a clinically meaningful early PASI response threshold. Methods: This prospective, multicenter real‐world cohort study (approval no. 2020‐36) included adult patients with moderate‐to‐severe plaque psoriasis receiving methotrexate, phototherapy, interleukin (IL)‐17 inhibitors, or IL‐23 inhibitors. Receiver operating characteristic (ROC) curve analyses were used to evaluate the predictive performance of week‐4 PASI improvement for achieving PASI90 at 3 and 6 months. The optimal early response threshold was identified using the Youden Index. Multivariable logistic regression analyses were conducted to assess the independent association between early PASI response and subsequent PASI90 achievement. Results: A total of 2023 patients were included in the analysis. The optimal week‐4 PASI improvement threshold for predicting PASI90 at 3 months was 62% for IL‐17 inhibitors, 62% for IL‐23 inhibitors, 59% for methotrexate, and 61% for phototherapy. Multivariable logistic regression analyses further demonstrated that a PASI improvement of approximately 60% at Week 4 was independently associated with a higher likelihood of achieving PASI90 at 3 months. Conclusions: Achieving PASI60 at Week 4 serves as a consistent early indicator of subsequent PASI90 response across multiple psoriasis treatment modalities. These findings suggest that PASI60 may represent a potentially generalizable early‐response threshold; however, external validation in independent populations is required before its incorporation into routine clinical decision‐making. Trial Registration: Chinese Clinical Trial Registry: ChiCTR2000036186
- Open Access
- 1 October 2025
- Published by Taylor & Francis in Psoriasis: Targets and Therapy
- Vol. ume 15, 513-525
Evaluating the Role of Disease Duration in Systemic Therapy Response Among Patients with Moderate-to-Severe Psoriasis
Background: Psoriasis is a chronic immune-mediated inflammatory disease. Systemic therapy is usually applicable to patients who have failed topical treatment or phototherapy, but the value of early systemic therapy remains unclear. Purpose: This study aimed to evaluate the impact of disease duration on the clinical efficacy and patients reported outcomes in moderate to severe psoriasis patients treated with systemic agents. Methods: Our research was based on the SPEECH, an observational, prospective, multicenter registry. Adult patients with moderate to severe psoriasis receiving systemic therapy (including biologics, methotrexate or acitretin) were divided into groups based on disease duration: <2 years, 2~10 years, and ≥10 years. The clinical efficacy was assessed using PASI (Psoriasis Area and Severity Index), BSA (Body Surface Area), PGA (Physician Global Assessment). The Dermatology Life Quality Index (DLQI), PtGA (Patient Global Assessment) and the Hospital Anxiety and Depression Scale (HADS) were used to assess the patients reported outcomes. The treatment outcomes were analyzed at 3 months and 6 months. Using multiple logistic regression to analyze the differences between patients with different disease duration, and conducting subgroup analysis and sensitivity analysis to test the robustness of the research results. Results: A total of 1908 patients who met the criteria were included in the analysis. After 3 months of treatment, the PASI75 response rates for the three groups of patients (0.05. No significant differences were observed among the three groups in the rates of achieving BSA <1/3, PGA 0/1, DLQI 0/1, PtGA 0/1, HADS-A = 0, and HADS-D = 0. Notably, these outcomes still showed no significant differences at 6 months. Subgroup and sensitivity analyses also yielded consistent results. Conclusion: Disease duration does not significantly affect clinical efficacy or patients reported outcomes in patients with moderate-to-severe psoriasis receiving systemic therapy. These results indicate that early systemic therapy does not improve treatment outcomes in real clinical settings, thereby supporting the continued efficacy of step-up treatment strategy and providing novel insights into clinical practice management.
- 1 October 2025
- Published by Taylor & Francis in Psoriasis: Targets and Therapy
- Vol. ume 15, 513-525
Open AccessEvaluating the Role of Disease Duration in Systemic Therapy Response Among Patients with Moderate-to-Severe Psoriasis
Background: Psoriasis is a chronic immune-mediated inflammatory disease. Systemic therapy is usually applicable to patients who have failed topical treatment or phototherapy, but the value of early systemic therapy remains unclear. Purpose: This study aimed to evaluate the impact of disease duration on the clinical efficacy and patients reported outcomes in moderate to severe psoriasis patients treated with systemic agents. Methods: Our research was based on the SPEECH, an observational, prospective, multicenter registry. Adult patients with moderate to severe psoriasis receiving systemic therapy (including biologics, methotrexate or acitretin) were divided into groups based on disease duration: <2 years, 2~10 years, and ≥10 years. The clinical efficacy was assessed using PASI (Psoriasis Area and Severity Index), BSA (Body Surface Area), PGA (Physician Global Assessment). The Dermatology Life Quality Index (DLQI), PtGA (Patient Global Assessment) and the Hospital Anxiety and Depression Scale (HADS) were used to assess the patients reported outcomes. The treatment outcomes were analyzed at 3 months and 6 months. Using multiple logistic regression to analyze the differences between patients with different disease duration, and conducting subgroup analysis and sensitivity analysis to test the robustness of the research results. Results: A total of 1908 patients who met the criteria were included in the analysis. After 3 months of treatment, the PASI75 response rates for the three groups of patients (0.05. No significant differences were observed among the three groups in the rates of achieving BSA <1/3, PGA 0/1, DLQI 0/1, PtGA 0/1, HADS-A = 0, and HADS-D = 0. Notably, these outcomes still showed no significant differences at 6 months. Subgroup and sensitivity analyses also yielded consistent results. Conclusion: Disease duration does not significantly affect clinical efficacy or patients reported outcomes in patients with moderate-to-severe psoriasis receiving systemic therapy. These results indicate that early systemic therapy does not improve treatment outcomes in real clinical settings, thereby supporting the continued efficacy of step-up treatment strategy and providing novel insights into clinical practice management.
- 24 April 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (9)
Comparative effects of biologics on anxiety and depression symptoms in psoriasis
- 24 April 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (9)
Comparative effects of biologics on anxiety and depression symptoms in psoriasis
- 5 November 2024
- Published by Wiley in Stress and Health
- Vol. 40 (6) , e3498
Association Between FABP7‐5‐HT Pattern and Anxiety or Depression in Patients With Psoriasis: A Cross‐Sectional Study
Psoriasis exhibits a higher incidence of anxiety and depression. However, the diagnostic process heavily relies on subjective evaluation. Fatty acid‐binding protein 7 (FABP7) and serotonin (5‐HT) are considered as potential plasma biomarkers. We aimed to investigate the potentiality of plasma FABP7 and 5‐HT as biomarkers for predicting anxiety and depression in psoriasis. Data were analysed from 140 patients with psoriasis in the Shanghai Psoriasis Effectiveness Evaluation CoHort (SPEECH). Unsupervised clustering was employed to group patients based on their FABP7 and 5‐HT profiles. Subsequently, patients were categorised into Group 1 (lower FABP7 and higher 5‐HT) or Group 2. Multivariate logistic regression was employed to investigate the correlation between the FABP7‐5‐HT pattern and anxiety or depression in psoriasis patients. Patients with psoriasis have a higher incidence of anxiety or depression, as well as higher levels of FABP7 and lower levels of 5‐HT. After clustering patients using K‐means clustering, Group 2 showed a higher body mass index, a higher incidence of hypertension, more severe psoriasis, and more significant anxiety and depression compared to Group 1. Multivariate logistic regression shows that adjusting for covariates except PASI, duration of psoriasis, and psoriatic arthritis, Group 2 had a higher risk of anxiety and depression compared to Group 1. Further adjustment for covariates yielded similar results. Pattern of FABP7‐5‐HT that may indicate an association with psoriasis accompanied by anxiety or depression.
- 5 November 2024
- Published by Wiley in Stress and Health
- Vol. 40 (6) , e3498
Association Between FABP7‐5‐HT Pattern and Anxiety or Depression in Patients With Psoriasis: A Cross‐Sectional Study
Psoriasis exhibits a higher incidence of anxiety and depression. However, the diagnostic process heavily relies on subjective evaluation. Fatty acid‐binding protein 7 (FABP7) and serotonin (5‐HT) are considered as potential plasma biomarkers. We aimed to investigate the potentiality of plasma FABP7 and 5‐HT as biomarkers for predicting anxiety and depression in psoriasis. Data were analysed from 140 patients with psoriasis in the Shanghai Psoriasis Effectiveness Evaluation CoHort (SPEECH). Unsupervised clustering was employed to group patients based on their FABP7 and 5‐HT profiles. Subsequently, patients were categorised into Group 1 (lower FABP7 and higher 5‐HT) or Group 2. Multivariate logistic regression was employed to investigate the correlation between the FABP7‐5‐HT pattern and anxiety or depression in psoriasis patients. Patients with psoriasis have a higher incidence of anxiety or depression, as well as higher levels of FABP7 and lower levels of 5‐HT. After clustering patients using K‐means clustering, Group 2 showed a higher body mass index, a higher incidence of hypertension, more severe psoriasis, and more significant anxiety and depression compared to Group 1. Multivariate logistic regression shows that adjusting for covariates except PASI, duration of psoriasis, and psoriatic arthritis, Group 2 had a higher risk of anxiety and depression compared to Group 1. Further adjustment for covariates yielded similar results. Pattern of FABP7‐5‐HT that may indicate an association with psoriasis accompanied by anxiety or depression.
- 30 March 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (11) , e920-e922
Efficacy and safety of oral abrocitinib monotherapy in pityriasis rubra pilaris
- 30 March 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (11) , e920-e922
Efficacy and safety of oral abrocitinib monotherapy in pityriasis rubra pilaris